Characterization of the Role of Breast Tumor Kinase (Brk) in Breast Cancer Cells Non-Responsive to EGFR-Targeted Agents

Abstract

Epidermal growth factor (EGF) receptor tyrosine kinases (erbB family), EGFR (erbB1) and HER2, are highly expressed in breast cancer and are associated with poor prognosis. A number of EGFR and/or HER2-targeted agents are being investigated for breast cancer treatment. Brk (Breast Tumor Kinase) is a nonreceptor tyrosine kinase that has been shown to enhance the mitogenic signaling of EGF, induce phosphorylation of erbB 3 and interact with AKT. In this study, we aim to investigate whether Brk can promote cells to become refractory to EGFR-targeted drugs. Pl-3 kinase/AKT pathway mediates EGF-induced cell growth and survival and is involved in cellular resistance to anti-cancer drugs. Because the P13K/AKT pathway is regulated by multiple activators, downregulation of the EGFR alone may not lead to its inhibition. We will investigate whether Brk promotes growth and survival as well as Pl3K/AKT activity in cells treated with EGFR-targeted agents.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2008
Accession Number
ADA490442

Entities

People

  • Anjaruwee S. Nimnual

Organizations

  • State University of New York

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biomedical Research
  • Breast Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Fractionation
  • Growth Factors
  • Inhibition
  • Inhibitors
  • Kinases
  • Neoplasms
  • Phosphorylation
  • Proteins
  • Regulations
  • Resistance
  • Survival

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.